We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Announces Fourth-Quarter and Full-Year 2013 Operating Results
Oral Rolapitant New Drug Application on Track for Submission to U.S. FDA in Mid-2014 Niraparib Phase 3 NOVA and BRAVO Trials Continue to Advance Cash and Cash Equivalents Totaled Approximately $130 Million as of December 31, 2013 Successful Follow-On Offering Raised Approximately $94 Million in
View HTML
Toggle Summary TESARO to Announce Fourth Quarter 2013 Financial Results on February 19, 2014
WALTHAM, Mass., Feb. 7, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its fourth quarter 2013 financial results on Wednesday, February 19, 2014, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15
View HTML
Toggle Summary TESARO to Present at Two Upcoming Investment Conferences
WALTHAM, Mass., Feb. 5, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President of TESARO, will participate in two investment conferences in February, including: The Leerink Swann Global Healthcare Conference at
View HTML
Toggle Summary TESARO Announces Pricing of Public Offering of Common Stock
WALTHAM, Mass., Jan. 29, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 3,200,000 shares of its common stock at a price to the public of $31.50 per share. The gross proceeds from the offering will be
View HTML
Toggle Summary TESARO Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., Jan. 28, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has commenced an underwritten public offering of $100 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional
View HTML
Toggle Summary TESARO to Present at the 32nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 7, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President of TESARO, will attend the 32nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco. Mr.
View HTML
Toggle Summary TESARO Announces Successful Achievement of Primary Endpoint in Each of Two Phase 3 Trials of Rolapitant for the Prevention of Chemotherapy-Induced Nausea & Vomiting (CINV)
A Phase 3 Trial in Patients Receiving Moderately Emetogenic Chemotherapy (MEC) Met the Primary Endpoint of Complete Response in the Delayed Period (24-120 Hours) Following Initiation of Chemotherapy A Phase 3 Trial in Patients Receiving Highly Emetogenic Chemotherapy (HEC) also Met the Primary
View HTML
Toggle Summary TESARO to Present at the 2013 Deutsche Bank BioFEST Conference
WALTHAM, Mass., Nov. 25, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President of TESARO, will present at the 2013 Deutsche Bank BioFEST conference at the Four Seasons Hotel in Boston on Monday, December 2,
View HTML
Toggle Summary TESARO Announces Third-Quarter 2013 Operating Results
Top-Line Results Expected to be Announced at Year-End 2013 from Two Phase 3 Trials of Oral Rolapitant Patient Enrollment in the Third Phase 3 Trial of Oral Rolapitant Expected to Conclude at Year End; Top-Line Results Now Anticipated in Early 2014 Dose Ranging Study of Intravenous Rolapitant
View HTML
Toggle Summary TESARO to Announce Third Quarter 2013 Financial Results on November 7, 2013
WALTHAM, Mass., Oct. 24, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its third quarter 2013 financial results on Thursday, November 7, 2013, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on
View HTML